Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
about
Long-term drug treatment for obesity: a systematic and clinical reviewLong-term effects of weight-reducing drugs in people with hypertensionCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Childhood obesity: prevention is better than cureThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityWeight management in obesity - past and presentAdvances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert ForumNeural control of energy balance: translating circuits to therapiesManaging obesity in primary care practice: an overview with perspective from the POWER-UP studyCan medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies.Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Current and emerging medications for overweight or obesity in people with comorbiditiesEfficacy comparison of medications approved for chronic weight managementNext generation of weight management medications: implications for diabetes and CVD riskAntiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term managementObesity: Current and potential pharmacotherapeutics and targets.Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity.Obesity and the need for bariatric surgery in Pakistan.New and emerging drug molecules against obesity.Antiobesity pharmacotherapy: new drugs and emerging targetsOptimal Pharmacologic Treatment Strategies in Obesity and Type 2 DiabetesPharmacotherapy of Obesity: Clinical Trials to Clinical Practice.Liraglutide and obesity: a review of the data so far.Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesityThe burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approachNew options for the treatment of obesity and type 2 diabetes mellitus (narrative review)A complications-based clinical staging of obesity to guide treatment modality and intensity.American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.The joint influence of gender and amount of smoking on weight gain one year after smoking cessation.Managing overweight and obesity in adults to reduce cardiovascular disease risk.Quantifying energy intake changes during obesity pharmacotherapy.Pharmacological management of binge eating disorder: current and emerging treatment options.Pharmacologic treatment options for obesity: what is old is new again.New pharmacological approaches for obesity management.Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.The importance of weight management in type 2 diabetes mellitus.Past and future corollaries of theories on causes of metabolic syndrome and obesity related co-morbidities part 2: a composite unifying theory review of human-specific co-adaptations to brain energy consumption.Longterm management of Polycystic Ovarian Syndrome (PCOS)
P2860
Q22253010-6798B6E6-4CF7-44A5-9267-09848497FB7EQ24186054-80CEDA93-FA2A-4DFA-B790-97859272F1BDQ26740253-6EEDDE98-FE2A-451A-AEE5-15DDFA84A7DDQ26752810-388995B2-5E90-4542-9216-A2E8DCB740FCQ26765609-D2F0BB05-B9D8-4EC2-A3A8-D7C7B4909E33Q26774747-4A4E76E5-E149-4BDE-8EE1-008C7240F90AQ26784022-F8A3F054-9EF7-46A2-8E3E-F8236A324D51Q27005992-A5984263-4FBF-4DC7-89CD-21DA9BB2A61AQ27010660-6120DBF9-B862-4F3C-B615-3DB620EE9730Q27015789-16361456-6613-47B5-A8B5-97B56AD965A2Q27331844-D5AC6E7F-E6E4-4128-8A3F-31D540AD2FEFQ27687851-43B97527-2A8F-4019-8C6A-2F5224CD419CQ28080825-94AA8A35-1CD1-45CE-8F62-EA070D47F777Q28081944-46ABCFB7-FE45-4F31-9DFA-9E6A382B7AB0Q28082858-9C0527CC-524A-4C23-A088-7C4F68497B44Q28084337-1198E467-DC72-4A59-9403-F95EAE3CE117Q30243992-2F1D7DB5-5D9D-4645-A8E7-B006238BB1C3Q30250304-AC78402B-DE23-48DF-850E-248AA16F4AB4Q30351930-842E8895-3A9B-41CF-ACE2-E4456EC24CFFQ30353872-3C7A4A73-917E-445A-AC83-4FB95AB1AF65Q30354242-B6FE8E57-C096-4B4A-A842-7143CBCB04CAQ30377441-D45A6EF2-BA32-4426-8F71-3C19384622FFQ30400748-12B55F21-66A0-4F48-8F20-87D83F101E31Q30924982-0F9222E6-BE7B-4A21-A534-86F8C6E23B4DQ33572190-94F2A441-BEA2-47D5-9AC7-EA0BB3E7FB32Q33750634-7E2EBD7B-B23C-4522-B816-85A38DF1543BQ33938171-9E50032A-2A2C-4EC3-A5F3-C57F1760DA0FQ34070610-13DBDF1E-93C6-4E16-BDAB-11697ACCC508Q34070626-7FF7D246-AD7E-4A96-92E8-3855831E8D48Q34081331-349FEBAC-7D87-4C80-9CF2-1B30908E67B4Q34086187-D9B0B14D-E0E2-4DBB-8FB4-88DE7139266AQ34106367-022F02FB-4D77-4967-ACD7-04474981D3B5Q34270377-EB914891-CE58-4209-B55C-A7F2E8AFFF2CQ34278450-F0BD9696-3DC4-462D-BF5E-853C471D8AA9Q34341681-921A69AD-DFA5-408F-A55F-373303E529B8Q34349850-D871BC0D-A03D-4397-AA9F-08D2D1BA2998Q34503739-E7C5EC61-9D47-4957-AC7B-58D3AADBE8C0Q34547464-C7F62538-56B2-476D-B0FE-BE36877AD82AQ35104485-B283B498-4446-4445-8382-73A758C02054Q35200094-E2B65261-8490-4A2F-BDE3-819703BD10C3
P2860
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Two-year sustained weight loss ...... olled, phase 3 extension study
@ast
Two-year sustained weight loss ...... olled, phase 3 extension study
@en
type
label
Two-year sustained weight loss ...... olled, phase 3 extension study
@ast
Two-year sustained weight loss ...... olled, phase 3 extension study
@en
prefLabel
Two-year sustained weight loss ...... olled, phase 3 extension study
@ast
Two-year sustained weight loss ...... olled, phase 3 extension study
@en
P2093
P2860
P356
P1476
Two-year sustained weight loss ...... olled, phase 3 extension study
@en
P2093
Charles H Bowden
Craig A Peterson
Kishore M Gadde
Michael Schwiers
Michelle Look
W Timothy Garvey
Wesley W Day
P2860
P304
P356
10.3945/AJCN.111.024927
P407
P577
2011-12-07T00:00:00Z